|
|
|
|
|
To continue building on what you've learned, we recommend the following Q&A article.
Explaining the Spray-Drying Process for Scale-Up and Commercialization
The use of spray drying to manufacture amorphous dispersions is continuing to
grow due to the number of drug candidates exhibiting poor solubility. In a Pharmaceutical Technology webcast, Jon Scrafford, Associate Director of Process
Engineering at Catalent, and Ryan Minikis, Principal at Arclight Pharmaceuticals, LLC,
explored the use of spray drying to create amorphous solid dispersions (ADSs) and the
optimization of process parameters for successful scale-up to commercial manufacture of
the final dosage form.
Read this article to get answers to several key questions about the spray-drying process.
|
|
|
|
|
|
Sponsored by:
|
|
|
|
